• Barrons.com

    Stocks Are Headed Higher in 2020, Strategists Say. Here’s Which Sectors Will Benefit the Most.

    Strategists see modest gains ahead for stocks in 2020, supported by a stable economy, accommodative monetary policy, and a pickup in manufacturing. Two wild cards: U.S.-China trade and the 2020 presidential election.

  • Hedge Funds Prefer Analog Devices Over ABB Ltd (ABB)
    Insider Monkey

    Hedge Funds Prefer Analog Devices Over ABB Ltd (ABB)

    How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]

  • Should You Worry About TTM Technologies, Inc.’s (NASDAQ:TTMI) ROCE?
    Simply Wall St.

    Should You Worry About TTM Technologies, Inc.’s (NASDAQ:TTMI) ROCE?

    Today we'll evaluate TTM Technologies, Inc. (NASDAQ:TTMI) to determine whether it could have potential as an...

  • Does Stoneridge, Inc.’s (NYSE:SRI) ROCE Reflect Well On The Business?
    Simply Wall St.

    Does Stoneridge, Inc.’s (NYSE:SRI) ROCE Reflect Well On The Business?

    Today we'll evaluate Stoneridge, Inc. (NYSE:SRI) to determine whether it could have potential as an investment idea...

  • The hottest housing markets of 2020 are far from the coasts
    MarketWatch

    The hottest housing markets of 2020 are far from the coasts

    Home buyers next year are expected to flock to smaller, more affordable cities, according to Realtor.com.

  • Garmin's Kao donates $20M to create institute within hospital
    American City Business Journals

    Garmin's Kao donates $20M to create institute within hospital

    The gift from the Kao Family Foundation will create the Kao Autoimmunity Institute to advance research and treatment of rheumatologic diseases at Cedars-Sinai Medical Center.

  • Texas Instruments Sees IBD RS Rating Rise To 75
    Investor's Business Daily

    Texas Instruments Sees IBD RS Rating Rise To 75

    A Relative Strength Rating upgrade for Texas Instruments shows improving technical performance. Will it continue?

  • Analysts Estimate CalAmp (CAMP) to Report a Decline in Earnings: What to Look Out for
    Zacks

    Analysts Estimate CalAmp (CAMP) to Report a Decline in Earnings: What to Look Out for

    CalAmp (CAMP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Garmin, Movado and Tesla highlighted as Zacks Bull and Bear of the Day
    Zacks

    Garmin, Movado and Tesla highlighted as Zacks Bull and Bear of the Day

    Garmin, Movado and Tesla highlighted as Zacks Bull and Bear of the Day

  • Bull of the Day: Garmin (GRMN)
    Zacks

    Bull of the Day: Garmin (GRMN)

    Bull of the Day: Garmin (GRMN)

  • Visteon Corporation (NASDAQ:VC) Might Not Be A Great Investment
    Simply Wall St.

    Visteon Corporation (NASDAQ:VC) Might Not Be A Great Investment

    Today we'll look at Visteon Corporation (NASDAQ:VC) and reflect on its potential as an investment. Specifically, we'll...

  • Texas Instruments (TXN) Dips More Than Broader Markets: What You Should Know
    Zacks

    Texas Instruments (TXN) Dips More Than Broader Markets: What You Should Know

    Texas Instruments (TXN) closed the most recent trading day at $121.37, moving -0.52% from the previous trading session.

  • Benzinga

    Large Option Traders Dumping Apple Puts Ahead Of Tariff Deadline

    Apple, Inc. (NASDAQ: AAPL) has been one of the hottest stocks in the market in 2019, gaining 70.8% and reaching a $1.2 trillion market cap. On Tuesday, Benzinga Pro subscribers received 34 option alerts related to unusually large trades of Apple options. At 9:11 a.m., a trader sold 2,792 Apple put options with a $240 strike price expiring on Feb. 21 near the bid price at $3.551.

  • Thomson Reuters StreetEvents

    Edited Transcript of VC earnings conference call or presentation 24-Oct-19 1:00pm GMT

    Q3 2019 Visteon Corp Earnings Call

  • Barrons.com

    2 Stocks to Buy to Play Growth of 5G Phones, According to an Analyst

    With 5G wireless mobile phones on the way, the time has come to buy shares of the key radio component vendors, according to BofA Global Research.

  • Is Delphi Technologies PLC (DLPH) Going To Burn These Hedge Funds ?
    Insider Monkey

    Is Delphi Technologies PLC (DLPH) Going To Burn These Hedge Funds ?

    Before putting in our own effort and resources into finding a good investment, we can quickly utilize hedge fund expertise to give us a quick glimpse of whether that stock could make for a good addition to our portfolios. The odds are not exactly stacked in investors' favor when it comes to beating the market, […]

  • American City Business Journals

    Year in Review 2019: Big M&A deals highlight Valley tech sector activity

    The most drawn-out and dramatic acquisition in the Phoenix region in 2019 came from Germany-based Merck KGaA and its $6.4 billion acquisition of Tempe's Versum Materials Inc.

  • Amazon Heightens Exposure in Sports With AWS-NFL Partnership
    Zacks

    Amazon Heightens Exposure in Sports With AWS-NFL Partnership

    Amazon's (AMZN) AWS teams up with National Football League to develop tools and technologies for players.

  • Should You Avoid Sensata Technologies Holding plc (ST)?
    Insider Monkey

    Should You Avoid Sensata Technologies Holding plc (ST)?

    Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]

  • Is Visteon Corp (VC) A Good Stock To Buy?
    Insider Monkey

    Is Visteon Corp (VC) A Good Stock To Buy?

    We can judge whether Visteon Corp (NASDAQ:VC) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas. There's no better way to get these firms' immense resources and analytical capabilities working for us than to follow their lead into their best ideas. […]

  • Here’s What Hedge Funds Think About ON Semiconductor Corporation (ON)
    Insider Monkey

    Here’s What Hedge Funds Think About ON Semiconductor Corporation (ON)

    Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Our research shows that most of the stocks that smart money likes historically generate strong […]

  • RBC: 3 “Strong Buy” Stocks That Could Step on the Gas in 2020
    TipRanks

    RBC: 3 “Strong Buy” Stocks That Could Step on the Gas in 2020

    The Cambridge Dictionary’s definition of an expert is a “person with a high level of knowledge or skill relating to a particular subject or activity.”Apply this to the investing world, and how do we see this in action? We pull out TipRanks’ Top Wall Street Firms and notice who sits at the top of the heap.Occupying the throne right now is renowned investment bank RBC Capital, which means that among the company’s employees there are seasoned pros with a proven track record for success. Utilizing the TipRanks Stock Screener tool, we’ve found three stocks receiving Strong Buy ratings from most analysts in general, and endorsed by RBC in particular. Let’s take a closer look: Ovid Therapeutics (OVID)Ovid Therapeutics shares are on a tear. The stock price of this neurological medicines firm has raced ahead 66% this year, leaving the Nasdaq Biotechnology ETF (IBB) in its dust. But would you believe it has even further to run? Would you believe it could go up another 200%? RBC analyst Brian Abrahams does. In his latest research note, Abrahams reiterated an Outperform rating on OVID, along with a price target of $12.00 (To watch Abraham’s track record, click here)The drug maker has several therapies in the pipeline. Leading programs in development right now are OV101, which focuses on a potential treatment for Angelman syndrome and Fragile X syndrome, two neurodevelopmental disorders caused by genetic mutations, and OV935, a program focused on developing potential therapies for people living with rare epilepsies.Top-line data from a Phase 3 NEPTUNE trial of OV101 in Angelman's Syndrome should be released in mid-2020, and Abrahams thinks there is a very reasonable chance of success. While acknowledging some risk given disease heterogeneity, unclear dose dependence, and inconsistent subdomain effects in ph.II, the 5-star analyst noted, “We believe clinical and preclinical data for the company's lead candidate OV101, an extrasynaptic GABAA receptor agonist, are in totality supportive of the drug's activity in Angelman Syndrome, and believe the stock price currently underappreciates the likelihood the drug succeeds in improving clinical symptoms of the disease in ph.III. Given the high unmet need in this population, we believe FDA will be permissive -- highlighted by the Agency's endorsement of the pivotal trial design -- and if approved, should enable good uptake and pricing power.”Other analysts are even more optimistic. Indeed, the average price target on Wall Street is $13.50 -- implying nearly 240% upside. And over the last three months, no one on the Street has assigned Ovid shares anything less than a "buy" rating. (See Ovid stock analysis on TipRanks)Anaplan (PLAN)This year has seen a number of car crash IPO’s, as several over valued startups got on the receiving end of a harsh reality check following public listings. One to avoid such a fate, is cloud computing ‘connected planning’ platform, Anaplan.The company’s name derives from the combination of analysis and planning, which makes sense to us, as it makes software that connects people in a shared environment to business data in order to make better-informed plans and decisions.Anaplan impressed Wall Street with its latest F3Q20 earnings report. The company handily beat expectations on several key metrics, including top-line, billings, and margins. Additionally, this led to management significantly boosting its FY20 guidance.RBC’s Alex Zukin believes that a ‘large addressable market’ can serve as a catalyst for Anaplan’s growth, noting, “Anaplan indicates that the Planning market is a $21B+ opportunity (based on IDC forecasts). We believe customers are paying legacy vendors billions of dollars today and there is potential for spend significantly above that if greenfield, excel-based business processes meaningfully start to convert to Planning vendors.”Anaplan’s growth potential has Zukin reiterating his Outperform rating, along with a price target of $70. PLAN is currently trading at $52.56, indicating gains of 33% might be in the cards should Zukin’s target materialize. (To watch Zukin’s track record, click here)What’s the Street’s plan for PLAN, then? The consensus is that the connected planning innovator is a Strong Buy, a rating achieved as a result of 9 "buy" and 3 "hold" ratings issued in the past 3 months. The average stock-price forecast of $63.33 implies upside potential of 20% from current levels. (See PLAN stock analysis on TipRanks)Analog Devices (ADI)Last and least, we come to semiconductor maker Analog Devices, which scored an "outperform" rating (i.e. "buy") from 5-star RBC analyst Mitch Steves.ADI stock is up nearly 38% in 2019 compared to the S&P 500, which has returned 24%. That’s impressive, but the big question for investors is whether the company (and its stock) can maintain the momentum. Steves suggests that if everything goes as planned, ADI will be a $136 stock in the next 12 months, implying about 18% return. (To watch Steves’ track record, click here)The company’s recent FQ4 numbers were mildly below Street expectations. Revenues of $1.44 billion slightly missed the Street’s estimate of $1.45 billion, while EPS of $1.19 came below the $1.22 estimate. FQ1 guidance also missed the Street’s targets.Steves commented, “We continue to believe that sentiment is still quite negative on the stock and remain positive as operating margin expansion should begin in Q2 and beyond [...] We remain positive on ADI and its suggestion of a recovery in Q2 is in line with our Analog view as well.” The analyst further added, “We are seeing positive trends within ADI’s communications business, as the company manages to sustain share gain and capture 5G opportunities. Being exposed to 5G radio content represents significant differentiation relative to the analog group, in our view.”The RBC expert is not alone in his take on ADI, as 11 Buys and 3 Holds from the analysts tracked by TipRanks over the last 3 months result in a Strong Buy consensus rating. The average price target stands at $125.57. (See ADI stock analysis on TipRanks)

  • Here's How P/E Ratios Can Help Us Understand Maxim Integrated Products, Inc. (NASDAQ:MXIM)
    Simply Wall St.

    Here's How P/E Ratios Can Help Us Understand Maxim Integrated Products, Inc. (NASDAQ:MXIM)

    This article is written for those who want to get better at using price to earnings ratios (P/E ratios). We'll apply a...

  • Barrons.com

    3 Tech Stocks With Generous Yields for 2020

    Cisco Systems, Taiwan Semiconductor Manufacturing, and Texas Instruments look like good buys for income-hungry investors, says one money manager.

  • Is Garmin Ltd. (GRMN) A Good Stock To Buy?
    Insider Monkey

    Is Garmin Ltd. (GRMN) A Good Stock To Buy?

    We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]